Comparative genomics groups phages of Negativicutes and classical Firmicutes despite different Gram-staining properties

Negativicutes are gram-negative bacteria characterized by two cell membranes, but they are phylogenetically a side-branch of gram-positive Firmicutes that contain only a single membrane. We asked whether viruses (phages) infecting Negativicutes were horizontally acquired from gram-negative Proteobacteria, given the shared outer cell structure of their bacterial hosts, or if Negativicute phages co-evolved vertically with their hosts and thus resemble gram-positive Firmicute prophages. We predicted and characterized 485 prophages (mostly Caudovirales) from gram-negative Firmicute genomes plus 2977 prophages from other bacterial clades, and we used virome sequence data from 183 human stool samples to support our predictions. The majority of identified Negativicute prophages were lambdoids closer related to prophages from other Firmicutes than Proteobacteria by sequence relationship and genome organization (position of the lysis module). Only a single Mu-like candidate prophage and no clear P2-like prophages were identified in Negativicutes, both common in Proteobacteria. Given this collective evidence, it is unlikely that Negativicute phages were acquired from Proteobacteria. Sequence-related prophages, which occasionally harboured antibiotic resistance genes, were identified in two distinct Negativicute orders (Veillonellales and Acidaminococcales), possibly suggesting horizontal cross-order phage infection between human gut commensals. Our results reveal ancient genomic signatures of phage and bacteria co-evolution despite horizontal phage mobilization.     

The return of the phage

Phages have been used to treat infectious diseases since their discovery nearly a century ago. Modern sequencing and genetic engineering technologies now enable researchers to vastly expand the use of phages as general drug delivery vehicles....it is only in the past five years that the regulatory guidelines for the approval of phage products—both in therapy and food safety—have been createdOver the past decade, bacteriophages have occasionally stirred public and media interest because of their potential as biological weapons against bacterial infections. Such reports have tended to come from Russian or Georgian laboratories, whereas Western research institutes and companies have usually found that phages do not live up to their promise. More than a decade later, however, the view of bacteriophages is set to change. Spurred on by advances in sequencing and other molecular techniques, research into phages has yielded its first applications. Not only are phages proving effective as therapeutic agents, but they are also playing a role in food safety and as delivery vehicles for drugs against a wide range of diseases.Interest in phages as therapeutic agents emerged almost immediately after their discovery nearly a century ago (Twort, 1915; d''Hérelle, 1917). This interest evaporated quickly in the West after the discovery of penicillin, but phage research was kept alive in the old Soviet Union and continued after its collapse in the 1990s. Ongoing studies there, although not always conforming to the most rigorous standards, provided the only evidence of the therapeutic potential of phages.Eventually, especially in the light of the increasing threat from drug-resistant bacteria, Western researchers turned to exploring phages again. However, it is only in the past five years that the regulatory guidelines for the approval of phage products—in both therapy and food safety—have been created. Previously, the US Food and Drug Administration (FDA) had lacked the appropriate regulatory measures; it took them four years to approve the first phage product for use in food safety in 2006. ListShield^TM is a cocktail of several phages that target Listeria monocytogenes, contaminants in meat and poultry products. Approvals for other food safety products have followed with greater speed (Sulakvelidze, 2011). Moreover, in 2008, the FDA approved the first phase 1 clinical trial of phages. This again involved a cocktail of eight phages to target various bacteria including Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli, in venous leg ulcers. This trial eventually established the safety of the phage preparation and cleared the way for more phage therapy trials (www.clinicaltrials.gov).The recent acceptance in the West of phages as anti-pathogenic agents was preceded by their use for diagnostic purposes to identify bacteria...The recent acceptance in the West of phages as anti-pathogenic agents was preceded by their use for diagnostic purposes to identify bacteria, according to Martin Loessner from the Institute of Food, Nutrition and Health in Zürich, Switzerland. “It then became possible to [...] harness the specificity of phage for applications such as recognition of the host cell, and also for reporter phage, which is a genetically modified phage with a gene so [you] can easily see the phage''s impact on the target cell,” he explained. “Later on we figured why not go and revisit the idea of using phages against pathogens.”This approach turned out to be highly successful against key food pathogens, Loessner said, because of the way phages work: “[T]he phage has been very finely tuned through zillions of generations in the evolutionary arms race, and is highly specific.” This specificity is important for targeting the few bacteria that cause food poisoning while sparing the bacteria in fermented food—such as soft cheeses—that are harmless and contribute flavour. “The phage is also immune to development of resistance by the host bacteria, because if not it would have become extinct a long time ago,” Loessner said.It is bacterial toxins that cause food poisoning rather than bacteria themselves, so phages are used as a preventive measure to stop the growth of bacteria such as Listeria in the first place. As such, it is important to bombard food products with a large number of phages to ensure that virtually all target bacteria are eradicated. “I always have this magic number of 10⁸, or 100 million per gram of food,” Loessner said. “In 1 g of food there are often only 500 target bacteria, so there is not enough to amplify the phage and you need really high numbers to kill the bacteria in one round of infection.” He added that, in his view, phages would soon become the main treatment for preventing bacterial contamination. “Phage in the near future will be the number one [treatment against] Listeria and Salmonella. It''s becoming number one already, especially in the US.”In Europe, the use of phages in food safety therapy is being held back by the requirement that foods treated with them are labelled as containing viruses, which means they are likely to meet consumer resistance, as happened with foods containing or made from genetically modified organisms. Loessner commented that education is required to raise awareness that the properly controlled use of phages involves minimal risk and could greatly enhance food safety. However, he also emphasized that the use of phages should represent an extra level of protection, not replace existing quality control measures....because phage lysins are often specific to a single bacterial genus, they would allow the specific targeting of pathogenic bacteriaThe ability of phages to target specific bacteria while leaving others alone also has great potential for treating bacterial infections, particularly in the light of increasing antibiotic resistance. Such treatments would not necessarily involve the phage themselves, but rather the use of their lysins—the enzymes that weaken the bacterial cell wall to allow newly formed viruses to exit the host cell. Lysins can be administered as antibiotics, at least for gram-positive bacteria that lack a separate outer membrane around the cell wall. Moreover, because phage lysins are often specific to a single bacterial genus, they would allow the specific targeting of pathogenic bacteria. “The fact that phage lysins leave the commensal microflora undisturbed is particularly significant,” commented Olivia McAuliffe, Senior Research Officer at the Teagasc Food Research Centre in Cork, Ireland. “Most of the antibiotics used clinically have broad-activity spectra and treatment with these antibiotics can have devastating effects on the normal flora, in particular for those taking long-term antibiotic courses.”Phages also have another great advantage over most conventional antibiotics in being potent against both dividing and non-dividing cells. “Because most antibiotics target pathways such as protein synthesis, DNA replication, and cell wall biosynthesis, they can only act when the cells are actively growing,” McAuliffe added. “Because lysins are enzymes, they will chew away the peptidoglycan in both viable and non-viable cells, dividing and non-dividing cells. This would be particularly important in the case of slow-growing organisms that cause infection, an example being Mycobacterium species.”This specificity of phages and their lysins is particularly important for treating chronic conditions resulting from persistent bacterial infection, particularly in the respiratory system or digestive tract. Broad-spectrum antibiotics also attack harmless and beneficial commensal bacteria, and can even worsen the condition by encouraging the growth of resistant bacteria. This is the case with Clostridium difficile, a cause of secondary infections and a major nosocomial (hospital-acquired) antibiotic-resistant pathogen, according to McAuliffe. It is a Gram-positive, rod-shaped, spore-forming bacterium that is the most serious and common cause of diarrhoea and other intestinal disease when competing bacteria in the gut flora have been wiped out by antibiotics. The bacterium and its spores, which form in aerobic conditions outside the body, are widespread in the environment and are present in the guts of 3% of healthy individuals and 66% of infants, according to the UK''s Health Protection Agency. Clostridium spreads readily on the hands of healthcare staff and visitors in hospitals. The ability of the bacteria to form spores resistant to heat, drying and disinfectants, which then adhere to surfaces, enables them to persist in the hospital environment.Because Clostridium is resistant to most conventional antibiotics, it has for some years usually been treated with metronidazole, which exploits the fact that Clostridium is anaerobic during infection. Metronidazole has proven particularly appealing as it has relatively little impact on human cells or commensal aerobic bacteria in the gut as it does not work in the presence of oxygen. But metronidazole does not always work, and physicians have therefore been using vancomycin, a stronger but more toxic antibiotic, as a last resort. Moreover, even in cases where antibiotics seem to eliminate Clostridium and cure the associated diarrhoea, infection recurs in as many as 20% of hospital patients (Kelly & LaMont, 2008). About one-fifth of these 20%, or 4% of the total number of patients succumbing to Clostridium, end up with a long-term infection that at present is difficult to eradicate.This is where phages step in, because they are well tolerated by patients and their specificity means that they will not target other gut bacteria. Clostridium phages have already been demonstrated to work selectively and there is the possibility of extracting lysins against Clostridium from the phage itself; an avenue being pursued by Aidan Coffey''s group at the Department of Biological Sciences at the Cork Institute of Technology in Bishoptown, Ireland.There is also growing interest in using phages to tackle various other infections that are resistant to existing drugs—for example, in wounds that fail to heal, which are a major risk for diabetics. The application of phages in such cases is not new—before penicillin it was often the only option—but the difference now is that modern molecular techniques for isolating bacterial strains from biopsies and matching them to phages greatly increases efficiency. One clinical trial, organized by the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, is currently recruiting patients to evaluate the use of phage preparations against a range of drug-resistant bacteria, including MRSA (methicillin-resistant Staphylococcus aureus), Enterococcus, Escherichia, Citrobacter, Enterobacter, Klebsiella, Shigella and Salmonella. The intention is to isolate bacterial strains from each patient and to identify matching phages from the Institute''s bacteriophage collection in Wrocław.Although the potential of phages or their lysins to combat bacterial pathogens, whether in food or those causing infectious diseases, has long been recognized, more recent work has identified new applications as delivery vehicles for vaccines or cytotoxic drugs to treat cancer. These applications do not exploit the phage''s natural targeting of bacteria, but make use of their ability to carry surface ligands that attract them to specific host cells.Even though phages do not attack human cells, they elicit an immune response and can be used as vectors to carry an engineered antigen on their surface to vaccinate against viral or bacterial disease. This approach has been tested in rabbits with a DNA vaccine against hepatitis B (Clark et al, 2011). The study compared the phage DNA vaccine with Engerix B—a commercially available vaccine based on a homologous recombinant protein—and found that the phage vaccine produced a significantly higher antibody response more quickly, as well as being potentially cheaper to produce and stable at a wider range of temperatures. This hepatitis B vaccine is now being developed by the UK biotech firm BigDNA in Edinburgh, Scotland, which has been granted a European patent, pending future clinical trials in humans.Modified phages could also serve as nanoparticles to deliver cytotoxic drugs straight to tumour cells, bypassing healthy cellsModified phages could also serve as nanoparticles to deliver cytotoxic drugs straight to tumour cells, bypassing healthy cells. Phages are a promising candidate vehicle because they can be readily engineered both to display appropriate ligands for targeting tumour cells specifically, and to carry a cytotoxic payload that is only released inside the target. One Israeli group has developed a technology for manufacturing phage nanoparticles that in principle can be used to target drugs to either tumour cells or pathogens (Bar et al, 2008). The group chose one particular phage family, known as filamentous phages, because of their small size and the relative ease of engineering them. Filamentous phages comprise just 10 genes with a sheath of several thousand identical α-helical coat proteins in a helical array assembled around a single-stranded circular DNA molecule. The Israeli scientists combine genetic modification and chemical engineering to create a phage that is able to attach to its target cell and release cytotoxic molecules. “Genetic engineering makes it possible to convert the phage to a targeted particle by displaying a target-specifying molecule on the phage coat,” explained Itai Benhar from Tel-Aviv University, the lead author of the paper. “Genetic engineering also makes it possible to design a drug-release mechanism. Finally chemical engineering makes it possible to load the particle with a large payload of cargo.”The group has used the same approach to target two bacteria species, Staphylococcus aureus and Escherichia coli, with the antibiotic chloramphenicol, which was first developed in 1949 but has raised concerns over its toxicity. According to the Israeli group, the phage nanoparticle loaded with the drug was 20,000 times more potent against both bacteria than the drug administered on its own. Just as importantly, the phage particles do not affect other cells. The overall advantage of the phage-based delivery approach is that it can deliver highly effective and toxic drugs in a safe way. The other point is that this and other methods in which phages are engineered to reach specific targets have nothing directly to do with the natural ability of phage viruses to attack bacteria. “The phage''s natural ability to infect bacteria is totally irrelevant to their application for targeting non-bacterial cells,” said Benhar. “In fact, they are not relevant for targeting bacteria either in this case, since the chemical modification we subject the phages to renders them non-infective.”However, the phage nanoparticles retain their immunogenic effect, which is a problem if the objective is merely to deliver a drug to the target while minimizing all other impacts. “Phages are immunogenic, and although we found a way to reduce their immunogenicity we did not totally eliminate it,” Benhar said. The other challenge is that, as the particles carry the payload drug on their surface, the physical and chemical properties change every time a new drug is loaded. Although the payload itself is inert until it reaches the target, the varying characteristics could alter the host response and therefore affect regulatory approval for each new phage construct, as safety would have to be demonstarted in each case.The use of phages is no longer confined to directly attacking infectious bacteria, but has vastly expanded in terms of methods, applications and the diseases that can be tackledNevertheless, this approach holds great promise as a novel way of delivering not just new drugs but also existing ones that are effective but too toxic for healthy cells. This is exactly the most exciting aspect of recent therapeutic phage research. The use of phages is no longer confined to directly attacking infectious bacteria, but has vastly expanded in terms of methods, applications and the diseases that can be tackled.     

人体肠道病毒组学研究进展

人体微生物组计划开展近10年来,大量的研究显示人体微生物通过各种方式深刻地影响着人体健康。人体肠道内丰富多样的病毒构成了肠道病毒组,是人体微生物组的重要组成部分,和人体健康密切相关。本文综述了近些年国际上人体肠道病毒组研究的最新进展,分别从人体肠道病毒组的组成特征、肠道病毒组-细菌组-人体间的相互作用及其对人体健康的影响、病毒组研究的技术策略及挑战等方面进行了论述,探讨了肠道病毒组在人体疾病预防和治疗领域应用的可行性。     

Phages and the Evolution of Bacterial Pathogens: from Genomic Rearrangements to Lysogenic Conversion

Comparative genomics demonstrated that the chromosomes from bacteria and their viruses (bacteriophages) are coevolving. This process is most evident for bacterial pathogens where the majority contain prophages or phage remnants integrated into the bacterial DNA. Many prophages from bacterial pathogens encode virulence factors. Two situations can be distinguished: Vibrio cholerae, Shiga toxin-producing Escherichia coli, Corynebacterium diphtheriae, and Clostridium botulinum depend on a specific prophage-encoded toxin for causing a specific disease, whereas Staphylococcus aureus, Streptococcus pyogenes, and Salmonella enterica serovar Typhimurium harbor a multitude of prophages and each phage-encoded virulence or fitness factor makes an incremental contribution to the fitness of the lysogen. These prophages behave like “swarms” of related prophages. Prophage diversification seems to be fueled by the frequent transfer of phage material by recombination with superinfecting phages, resident prophages, or occasional acquisition of other mobile DNA elements or bacterial chromosomal genes. Prophages also contribute to the diversification of the bacterial genome architecture. In many cases, they actually represent a large fraction of the strain-specific DNA sequences. In addition, they can serve as anchoring points for genome inversions. The current review presents the available genomics and biological data on prophages from bacterial pathogens in an evolutionary framework.     

Prophage Tracer: precisely tracing prophages in prokaryotic genomes using overlapping split-read alignment

The life cycle of temperate phages includes a lysogenic cycle stage when the phage integrates into the host genome and becomes a prophage. However, the identification of prophages that are highly divergent from known phages remains challenging. In this study, by taking advantage of the lysis-lysogeny switch of temperate phages, we designed Prophage Tracer, a tool for recognizing active prophages in prokaryotic genomes using short-read sequencing data, independent of phage gene similarity searching. Prophage Tracer uses the criterion of overlapping split-read alignment to recognize discriminative reads that contain bacterial (attB) and phage (attP) att sites representing prophage excision signals. Performance testing showed that Prophage Tracer could predict known prophages with precise boundaries, as well as novel prophages. Two novel prophages, dsDNA and ssDNA, encoding highly divergent major capsid proteins, were identified in coral-associated bacteria. Prophage Tracer is a reliable data mining tool for the identification of novel temperate phages and mobile genetic elements. The code for the Prophage Tracer is publicly available at https://github.com/WangLab-SCSIO/Prophage_Tracer.     

Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion.

Comparative genomics demonstrated that the chromosomes from bacteria and their viruses (bacteriophages) are coevolving. This process is most evident for bacterial pathogens where the majority contain prophages or phage remnants integrated into the bacterial DNA. Many prophages from bacterial pathogens encode virulence factors. Two situations can be distinguished: Vibrio cholerae, Shiga toxin-producing Escherichia coli, Corynebacterium diphtheriae, and Clostridium botulinum depend on a specific prophage-encoded toxin for causing a specific disease, whereas Staphylococcus aureus, Streptococcus pyogenes, and Salmonella enterica serovar Typhimurium harbor a multitude of prophages and each phage-encoded virulence or fitness factor makes an incremental contribution to the fitness of the lysogen. These prophages behave like "swarms" of related prophages. Prophage diversification seems to be fueled by the frequent transfer of phage material by recombination with superinfecting phages, resident prophages, or occasional acquisition of other mobile DNA elements or bacterial chromosomal genes. Prophages also contribute to the diversification of the bacterial genome architecture. In many cases, they actually represent a large fraction of the strain-specific DNA sequences. In addition, they can serve as anchoring points for genome inversions. The current review presents the available genomics and biological data on prophages from bacterial pathogens in an evolutionary framework.     

The changing hypothesis of the gut. The intestinal microbiome is increasingly seen as vital to human health

A rise in immune-related diseases has coincided with increasing levels of hygiene and antibiotic use. In our war against bacteria, are our gut microbiota collateral damage, and can we afford to lose their proven health effects?In many ways, humankind''s story of the past two centuries is that of a battle against dirt. From the development of the germ theory of disease to the modernization of sewerage systems in large cities, our growing awareness of the microorganisms and diseases that come with dirt has led to better public health and better hygiene. Yet, despite the increased lifespans and reduced infant mortality that have partly resulted from such improvements, the medical establishment has seen an increase in allergies and autoimmune diseases in the industrialized world in recent decades.… the medical establishment has […] seen an increase in allergies and autoimmune diseases in the industrialized world in recent decadesSeveral hypotheses have been put forward to explain the trend, ranging from exposure to environmental contaminants to changing diets. Yet none so far have given an entirely satisfactory answer. One of the most interesting suggestions that has enjoyed some popularity, but has never caught on with many researchers or clinicians, is the hygiene hypothesis, which suggests that humanity''s new-found cleanliness is itself the problem. The hypothesis, which was first proposed more than two decades ago [1], posits that childhood exposure to pathogenic organisms, especially certain bacteria, is essential for training the immune system to become tolerant of the many neutral or benevolent strains of microbiota that enter or reside in our bodies; without this exposure, the immune system overreacts to environmental cues. The problem with the hypothesis, though, is not that it is demonstrably wrong, but that it remains incomplete and has so-far lacked hard evidence of a link between exposure to pathogens and specific immunological mechanisms.In the post-genomic era, however, a new and more complete theory has emerged to explain the rise in allergic and autoimmune diseases. The ‘disappearing microbiota'' hypothesis does not point the finger at any single aspect of modern life, but suggests instead that some—if not all—developments over the past century, such as clean water, modern birth practices, pollution and the increasing use of antibiotics, have all contributed to a shift in the balance between different species and types of microorganism in the gut. This shift has, in turn, altered our symbiotic relationship with our gut microflora and the health benefits that our tiny passengers have conferred on us in the past.The disappearing microbiota theory has emerged with our growing knowledge of the importance of the microbiome in immunity and health [2]. One important implication is that changes in the composition of the microbiome, at the population level, must have consequences—potentially both positive and negative—and that these must be taken account of in health policy. “We and others have proposed the microbiota hypothesis,” said Sarkis Mazmanian, an Assistant Professor in the Division of Biology at the California Institute of Technology and a specialist in the evolutionary mechanisms of host–bacterial symbiosis. “It is not reduced infections that are mediating increases in allergic and autoimmune disease, as proposed by the hygiene hypothesis, but the lack of exposure to gut bacteria, as in the microbiota hypothesis” [3].According to Martin Blaser from the New York University School of Medicine, well known for his studies of the link between Helicobacter pylori and human diseases, this lack of exposure to gut bacteria is leading to a gradual shrinking of the human microbiome, at least in affluent nations. “This is the disappearing microbiota hypothesis,” Blaser said. “I came to this hypothesis through my work on Helicobacter, which is clearly disappearing. But the disappearance seems to have begun even before Helicobacter was discovered, and not because people are treating ulcers,” he explained, referring to the common practice of treating stomach ulcers with antibiotics designed to kill Helicobacter, following the discovery of its causal link with the condition [3].In fact, Blaser suggests that various factors are involved, including the overuse of antibiotics, as well as the chlorination of drinking water. “We know that chlorination of water impedes the spread of pathogens, but another thought is that it impedes the spread of commensals,” he explained. But Blaser does not think we should stop chlorinating water, nor does he want to turn back the clock on antibiotics. Even so, he does make an important point: “Antibiotics are wonder drugs, but everyone assumed they would be free, with no biological cost. When you start learning about our microbiome, it''s not too hard to imagine courses of antibiotics leading to extinctions, and when [the commensals] are gone, they''re gone. It was assumed that everything bounces back when the course is over, but there is more and more evidence that this is not the case.” Indeed, Blaser believes that the microbiome is gradually disappearing in terms of the total number of species present, but that this is hard to spot when there are so many and their numbers are so variable between individuals. “If you have thousands of species, you may not see it at first, but our hypothesis is that it is cumulative,” he explained.Regardless of whether the microbiome is shrinking in diversity, the idea that it is profoundly important in human health is gaining credibility, most immediately in inflammatory conditions directly relating to the gut, such as irritable bowel syndrome (IBS). Virtually nobody in the field disputes the idea that the microbiome is implicated in IBS, but it is less clear whether it is a cause, an effect, or a combination of both. The question is whether conditions such as IBS are caused by a priori changes in the microbiome, or whether such changes are symptoms of diagnostic value.The latest evidence that the micriobota have a protective effect in the gut comes from a recent study using mice [5]. Richard Flavell and colleagues at the Yale School of Medicine found that deficiencies in the NLRP6 inflammasome, engineered by a deletion mutation, resulted in an imbalance in the gut microbiota. The new micriobiota population was colitogeneic and led to inflammation of the colon. “But more importantly, we found that this pro-colitogenic flora was transmissible to wild-type mice that were co-housed with NLRP6 inflammasome-deficient mice, and induced exacerbated inflammatory bowel disease (IBD) in both NLRP6-deficient and co-housed wild-type mice,” Flavell explained.The ‘disappearing microbiota'' hypothesis […] suggests […] developments over the past century […] contributed to a shift in the […] species and types of microorganism in the gutIn other words, IBD can be transmitted to healthy animals that are not NLRP6 deficient, possibly through the spread of commensal bacteria or their products, such as metabolites, that might induce a change in the microflora. As Flavell indicated, although the NLRP6 inflammasome is known broadly to regulate the composition of the microbiota through release of the pro-inflammatory signalling cytokine interleukin-18 (IL-18), his latest work raises questions over the specifics of this process. “What types of microbial components or metabolites activate the NLRP6 inflammasome and how IL-18 regulates the ecology of the gut microbiota are important questions that remain to be resolved in the near future,” he said.This finding that metabolic conditions can be transferred to otherwise-healthy individuals should be followed up to see if it can be replicated in other animal models and ultimately in humans. This is of particular interest, given that the causes for the recent near-epidemic of obesity among some population groups have yet to be fully explained.Perhaps more probable, however, is that a change in the microbiome follows the onset of a condition such as obesity, rather than being the underlying cause. Even so, it might still be possible to reverse the syndrome by forcing a change in the composition of commensal bacteria in the gut. Work by Willem de Vos and colleagues at the Laboratory of Microbiology, Wageningen University, the Netherlands, is examining the potential for prebiotic and probiotic therapies that can be tested on humans, partly on existing published data from human and animal research [6].Another important indication emerging from the work of Flavell, de Vos and others is that the influence of the microbiome extends beyond metabolic disorders, for which few dispute the importance of commensal bacteria, to include disorders affecting a variety of organs and systems elsewhere in the body. In the case of some inflammatory liver diseases, this link was already known. There is a strong association, for example, between inflammatory gastrointestinal diseases—such as ulcerative colitis and the chronic liver disease primary sclerosing cholangitis, which involves scarring of the bile ducts of the liver [7]—and the presence of commensal bacteria. Flavell and colleagues found that dysbiosis associated with deficiency in the inflammasome regulates hepatic inflammatory processes in non-alcoholic fatty liver disease [8], which is highly prevalent in western societies. This study found that wild-type mice co-housed with inflammasome-deficient mice developed exacerbated steatohepatitis—a type of liver disease—as well as obesity, suggesting there is also a contagious element to some liver diseases.The liver is anatomically close to the intestines, but there is growing evidence that the influence of the microbiome permeates organs and systems elsewhere in the body, including the central nervous system. Studies have evaluated evidence for connections between the microbiome and multiple sclerosis, for example, suggesting that it could have potential both for diagnosis and therapies in future. Glenn Gibson, Professor of Food Microbial Sciences at the University of Reading in the UK, commented that such findings are “not too surprising because the metabolic output of gut bacteria is massive and bound to exert effects locally as well as systemically.” He explained that the effects “can be positive or negative for health, depending on which bugs and which metabolites are involved. But the really great news is that we are able to alter the situation to improve things and affect health. Unlike our genetics, the gut microbiome can be changed.” If, as Gibson suggests, the gut microbiome is responsible for about 70% of the total immune response, this could have profound consequences for the treatment of disease.However, for treatments based on probiotics or metabolites derived from bacteria to become widely available, there will have to be a marked shift in the attitude of some regulators, according to Gregor Reid, Chair in Human Microbiology and Probiotics at the Lawson Health Research Institute in London, Ontario, Canada. Reid and colleagues have conducted trials on the use of probiotic lactobacilli, a main component of the lactic acid bacteria group, to improve the treatment of vulvovaginal candidiasis (VVC) [9]. This is a condition caused by a strain of yeast that affects around 75% of sexually active women at some stage of their lives, causing vaginal itching and discharge. Reid was incensed when the European Food Safety Authority (EFSA) refused to approve this probiotic treatment for VVC in the European Union, leading to his publication of an opinion paper countering the EFSA critique [10]. “In this recent EFSA ruling, they stupidly disassociated nutrition from vaginal health, when in fact it is critical,” Reid explained.“When you start learning about our microbiome, it''s not too hard to imagine courses of antibiotics leading to extinctions…”At least this incident has highlighted issues relating to the use of, and approval for, treatments that attempt to alleviate conditions through manipulation of the microbiome. In particular, it highlights the need to nail down direct molecular associations between components of the human microbiome and specific cells or systems in the body that underpin conditions such as VVC. This is a main focus of research at the Functionality of the Intestinal Ecosystem (FinE) lab at the Micalis Institute in Paris, France. “The major priority of my own research team is to use functional metagenomics to identify signal molecules and crosstalk mechanisms linking human intestinal commensals and human cells using in vitro high throughput phenotyping systems,” explained Joël Doré, Vice Head of FinE. “The basic concept is that intestinal commensals constantly exchange signals with human cells, including intestinal epithelial cells, immune cells and even distally located peripheral tissues from adipose tissue to liver to brain.”It is probable that new diagnostic approaches will emerge from such metagenomic work on commensals even before treatments, which require a greater burden of proof and longer cycles of approval. It is not just regulators, but pharmaceutical companies that will have to embrace the idea of probiotics and metabolites before treatments become widely available in mainstream health care. There is great optimism from researchers in the field, but they still have to convince regulators and big pharma companies that the microbiome will become a main source of new therapies.     

Classification and quantification of bacteriophage taxa in human gut metagenomes

Bacteriophages have key roles in microbial communities, to a large extent shaping the taxonomic and functional composition of the microbiome, but data on the connections between phage diversity and the composition of communities are scarce. Using taxon-specific marker genes, we identified and monitored 20 viral taxa in 252 human gut metagenomic samples, mostly at the level of genera. On average, five phage taxa were identified in each sample, with up to three of these being highly abundant. The abundances of most phage taxa vary by up to four orders of magnitude between the samples, and several taxa that are highly abundant in some samples are absent in others. Significant correlations exist between the abundances of some phage taxa and human host metadata: for example, ‘Group 936 lactococcal phages'' are more prevalent and abundant in Danish samples than in samples from Spain or the United States of America. Quantification of phages that exist as integrated prophages revealed that the abundance profiles of prophages are highly individual-specific and remain unique to an individual over a 1-year time period, and prediction of prophage lysis across the samples identified hundreds of prophages that are apparently active in the gut and vary across the samples, in terms of presence and lytic state. Finally, a prophage–host network of the human gut was established and includes numerous novel host–phage associations.     

Sustainability of Virulence in a Phage-Bacterial Ecosystem

Virulent phages and their bacterial hosts represent an unusual sort of predator-prey system where each time a prey is eaten, hundreds of new predators are born. It is puzzling how, despite the apparent effectiveness of the phage predators, they manage to avoid driving their bacterial prey to extinction. Here we consider a phage-bacterial ecosystem on a two-dimensional (2-d) surface and show that homogeneous space in itself enhances coexistence. We analyze different behavioral mechanisms that can facilitate coexistence in a spatial environment. For example, we find that when the latent times of the phage are allowed to evolve, selection favors “mediocre killers,” since voracious phage rapidly deplete local resources and go extinct. Our model system thus emphasizes the differences between short-term proliferation and long-term ecosystem sustainability.The replication strategies of phages fall into two major categories: virulent and temperate. A temperate phage has the ability to integrate its DNA into the host chromosome, where it is then replicated along with the bacterial DNA during cell division. This strategy allows the phage to slow down or completely stop exploitation of the bacteria, thus reducing the risk of driving its host to extinction. A virulent phage lacks this ability, and it is not fully understood how they manage to coexist with their bacterial prey (4, 19). Consider, for example, the highly effective T4 phage. For the sake of argument, let us assume a burst size of 100 offspring upon lysis. On average, not more than a single phage out of each burst of 100 should survive to infect another bacterium, or else the phage would rapidly outgrow the bacteria and drive them to extinction. The half-life (t_1/2) of a free T4 phage particle has been measured to be approximately 10 days in LB at 37°C (6). Therefore, on average, at least t_1/2 × log₂(100) ≈ 2 months should pass between infections to prevent runaway phage growth—a time span that seems highly unreasonable for many of the environments where phage and bacteria interact, such as soil or biofilm. Even a more considered calculation, inserting the above half-life measurement into more realistic Lotka-Volterra-like predator-prey models (9) does not change the conclusion that T4 and other virulent phages appear to be far too effective predators for coexistence to be feasible. It is, however, an undisputed fact that virulent phages and bacteria have coexisted for eons and do so still, everywhere around us and inside us. One possible explanation for this puzzle is that bacteria constantly evolve resistance to existing phages and that the phages evolve to attack resistant bacteria in a continuous arms race. This “Red Queen” argument (23) has, however, been criticized on the grounds that the rates of evolution of phages and bacteria are not symmetric (17, 12). Recent measurements support this: in soil, phages appear to be “ahead of the bacteria in the coevolutionary arms race” (24). We therefore wish to explore mechanisms other than bacterial resistance that may promote coexistence between virulent phages and bacteria.Historically, phage-bacterial ecosystem models have ignored the issue of space, utilizing zero-dimensional approaches, such as ordinary differential equations (e.g., see references 1, 5, 13, 14, 15, and 21). However, many real phage-bacterial ecosystems are found in environments with a complex spatial structure, such as soil, biofilms, or wounds in animal and plant tissue. Schrag and Mittler (20) showed that coexistence between virulent phage and bacteria is feasible in a chemostat but not in serial cultures, due to the heterogeneous nature of the environment in the chemostat. Further, experiments done by Brockhurst et al. (3) indicate that reduced phage dispersal can prolong coexistence for virulent phage and bacteria in spatial environments by creating ephemeral refuges for the bacteria. Kerr et al. (10) introduced a simple cellular automaton to model fragmented populations of phage and bacteria in which coexistence was more easily achieved when migration was spatially restricted. Thus, the main extension to the simple predator-prey framework that we examine will be to add a spatial dimension.We construct and compare two phage-bacterial ecosystem models: one model where the phage and bacteria exist in a two-dimensional space, such as the surface of an agar gel (referred to as the “spatial model”), and the other model where the phage and bacteria are repeatedly mixed, mimicking serial cultures or a well-mixed broth (referred to as the “well-mixed model”). We show that space does indeed enhance coexistence. We then move on to explore other mechanisms that phage could incorporate into their behavior to further enhance coexistence. These can broadly be classified as “hardwired” (where every phage follows the same deterministic strategy) versus “adaptive” (where each phage potentially behaves differently, thus allowing the population to explore different options).We have chosen to look at three specific mechanisms as examples of these categories: (i) phage effectiveness would be reduced if they were unable to register whether they were infecting live, infected, or dead bacteria (a hardwired behavior); (ii) phage could prolong their latent time, concurrently increasing burst size, depending on the number of multiple infections (also a hardwired behavior, but a more “active” sort, where each phage senses and responds to information from the environment; T4 is known to use such a lysis inhibition strategy), and (iii) phage offspring could have altered latent times due to mutations in the holin genes (an adaptive behavior). We will compare each of these mechanisms in the spatial and well-mixed models to investigate whether the heterogeneity possible in a spatial environment affects the outcome.     

The novel anti-CRISPR AcrIIA22 relieves DNA torsion in target plasmids and impairs SpyCas9 activity

To overcome CRISPR-Cas defense systems, many phages and mobile genetic elements (MGEs) encode CRISPR-Cas inhibitors called anti-CRISPRs (Acrs). Nearly all characterized Acrs directly bind Cas proteins to inactivate CRISPR immunity. Here, using functional metagenomic selection, we describe AcrIIA22, an unconventional Acr found in hypervariable genomic regions of clostridial bacteria and their prophages from human gut microbiomes. AcrIIA22 does not bind strongly to SpyCas9 but nonetheless potently inhibits its activity against plasmids. To gain insight into its mechanism, we obtained an X-ray crystal structure of AcrIIA22, which revealed homology to PC4-like nucleic acid–binding proteins. Based on mutational analyses and functional assays, we deduced that acrIIA22 encodes a DNA nickase that relieves torsional stress in supercoiled plasmids. This may render them less susceptible to SpyCas9, which uses free energy from negative supercoils to form stable R-loops. Modifying DNA topology may provide an additional route to CRISPR-Cas resistance in phages and MGEs.

Derived from phages of the gut microbiome, this study describes a CRISPR-Cas9 inhibitor with an unexpected mechanism; instead of binding Cas9 itself, this “anti-CRISPR” relaxes plasmid DNA and enables Cas9 evasion, suggesting that DNA topology is an underappreciated battleground in phage-bacterial conflicts.     

Bacteria, phages and septicemia

The use of phages is an attractive option to battle antibiotic resistant bacteria in certain bacterial infections, but the role of phage ecology in bacterial infections is obscure. Here we surveyed the phage ecology in septicemia, the most severe type of bacterial infection. We observed that the majority of the bacterial isolates from septicemia patients spontaneously secreted phages active against other isolates of the same bacterial strain, but not to the strain causing the disease. Such phages were also detected in the initial blood cultures, indicating that phages are circulating in the blood at the onset of sepsis. The fact that most of the septicemic bacterial isolates carry functional prophages suggests an active role of phages in bacterial infections. Apparently, prophages present in sepsis-causing bacterial clones play a role in clonal selection during bacterial invasion.     

A method for generation phage cocktail with great therapeutic potential

Background

Bacteriophage could be an alternative to conventional antibiotic therapy against multidrug-resistant bacteria. However, the emergence of resistant variants after phage treatment limited its therapeutic application.

Methodology/Principal Findings

In this study, an approach, named “Step-by-Step” (SBS), has been established. This method takes advantage of the occurrence of phage-resistant bacteria variants and ensures that phages lytic for wild-type strain and its phage-resistant variants are selected. A phage cocktail lytic for Klebsiella pneumoniae was established by the SBS method. This phage cocktail consisted of three phages (GH-K1, GH-K2 and GH-K3) which have different but overlapping host strains. Several phage-resistant variants of Klebsiella pneumoniae were isolated after different phages treatments. The virulence of these variants was much weaker [minimal lethal doses (MLD)>1.3×10⁹ cfu/mouse] than that of wild-type K7 countpart (MLD = 2.5×10³ cfu/mouse). Compared with any single phage, the phage cocktail significantly reduced the mutation frequency of Klebsiella pneumoniae and effectively rescued Klebsiella pneumoniae bacteremia in a murine K7 strain challenge model. The minimal protective dose (MPD) of the phage cocktail which was sufficient to protect bacteremic mice from lethal K7 infection was only 3.0×10⁴ pfu, significantly smaller (p<0.01) than that of single monophage. Moreover, a delayed administration of this phage cocktail was still effective in protection against K7 challenge.

Conclusions/Significance

Our data showed that the phage cocktail was more effective in reducing bacterial mutation frequency and in the rescue of murine bacteremia than monophage suggesting that phage cocktail established by SBS method has great therapeutic potential for multidrug-resistant bacteria infection.     

Bioinformatics Analysis of Antimicrobial Resistance Genes and Prophages Colocalized in Human Gut Metagenomes

The constant increase of bacterial antibiotic-resistant strains is directly linked to a common use of antibiotics in medicine and animal breeding. It is suggested that the gut microbiota serves as a reservoir for antibiotic resistance genes that can be transferred from symbiotic bacteria to pathogenic ones, particularly due to phage transduction. In this study, using the PHASTER prophage predicting tool and CARD antibiotics resistance database we have searched for antibiotic resistance genes that are located within prophages in human gut microbiota. After analysing metagenomic assemblies of eight samples of antibiotic treated patients, lsaE, mdfA, and cpxR/cpxA genes were identified inside prophages. These genes confer resistance to antimicrobial peptides, pleuromutilin, lincomycins, streptogramins and also multidrug resistance. Three (0.46%) of 659 putative prophages predicted in the metagenomic assemblies contained antibiotics resistance genes in their sequences.     

Carriage of λ Latent Virus Is Costly for Its Bacterial Host due to Frequent Reactivation in Monoxenic Mouse Intestine

Temperate phages, the bacterial viruses able to enter in a dormant prophage state in bacterial genomes, are present in the majority of bacterial strains for which the genome sequence is available. Although these prophages are generally considered to increase their hosts’ fitness by bringing beneficial genes, studies demonstrating such effects in ecologically relevant environments are relatively limited to few bacterial species. Here, we investigated the impact of prophage carriage in the gastrointestinal tract of monoxenic mice. Combined with mathematical modelling, these experimental results provided a quantitative estimation of key parameters governing phage-bacteria interactions within this model ecosystem. We used wild-type and mutant strains of the best known host/phage pair, Escherichia coli and phage λ. Unexpectedly, λ prophage caused a significant fitness cost for its carrier, due to an induction rate 50-fold higher than in vitro, with 1 to 2% of the prophage being induced. However, when prophage carriers were in competition with isogenic phage susceptible bacteria, the prophage indirectly benefited its carrier by killing competitors: infection of susceptible bacteria led to phage lytic development in about 80% of cases. The remaining infected bacteria were lysogenized, resulting overall in the rapid lysogenization of the susceptible lineage. Moreover, our setup enabled to demonstrate that rare events of phage gene capture by homologous recombination occurred in the intestine of monoxenic mice. To our knowledge, this study constitutes the first quantitative characterization of temperate phage-bacteria interactions in a simplified gut environment. The high prophage induction rate detected reveals DNA damage-mediated SOS response in monoxenic mouse intestine. We propose that the mammalian gut, the most densely populated bacterial ecosystem on earth, might foster bacterial evolution through high temperate phage activity.     

Comparative Analysis of the Intestinal Bacterial and RNA Viral Communities from Sentinel Birds Placed on Selected Broiler Chicken Farms

There is a great deal of interest in characterizing the complex microbial communities in the poultry gut, and in understanding the effects of these dynamic communities on poultry performance, disease status, animal welfare, and microbes with human health significance. Investigations characterizing the poultry enteric virome have identified novel poultry viruses, but the roles these viruses play in disease and performance problems have yet to be fully characterized. The complex bacterial community present in the poultry gut influences gut development, immune status, and animal health, each of which can be an indicator of overall performance. The present metagenomic investigation was undertaken to provide insight into the colonization of specific pathogen free chickens by enteric microorganisms under field conditions and to compare the pre-contact intestinal microbiome with the altered microbiome following contact with poultry raised in the field. Analysis of the intestinal virome from contact birds (“sentinels”) placed on farms revealed colonization by members of the Picornaviridae, Picobirnaviridae, Reoviridae, and Astroviridae that were not present in pre-contact birds or present in proportionally lower numbers. Analysis of the sentinel gut bacterial community revealed an altered community in the post-contact birds, notably by members of the Lachnospiracea/Clostridium and Lactobacillus families and genera. Members of the avian enteric Reoviridae and Astroviridae have been well-characterized and have historically been implicated in poultry enteric disease; members of the Picobirnaviridae and Picornaviridae have only relatively recently been described in the poultry and avian gut, and their roles in the recognized disease syndromes and in poultry performance in general have not been determined. This metagenomic analysis has provided insight into the colonization of the poultry gut by enteric microbes circulating in commercial broiler flocks, and has identified enteric viruses and virus communities that warrant further study in order to understand their role(s) in avian gut health and disease.     

Characterization of the human DNA gut virome across populations with different subsistence strategies and geographical origin

It is a matter of fact that the human gut microbiome also includes a non‐bacterial fraction represented by eukaryotic cells and viruses. To further explore the gut microbiome variation in human populations, here we characterized the human DNA viral community from publicly available gut metagenome data sets from human populations with different geographical origin and lifestyle. In particular, such data sets encompass microbiome information from two western urban societies (USA and Italy), as well as two traditional hunter‐gatherer communities (the Hadza from Tanzania and Matses from Peru) and one pre‐agricultural tribe (Tunapuco from Peru). Our results allowed for the first taxonomic reconstruction of the complex viral metacommunities within the human gut. The core virome structure included herpesviruses, papillomaviruses, polyomaviruses, adenoviruses and anelloviruses. Using Random Forests and a co‐occurrence analysis approach, we identified the viruses that distinguished populations according to their geographical origin and/or lifestyle. This paves the way for new research aimed at investigating the biological role of the gut virome in human physiology, and the importance of our viral counterpart in the microbiome‐host co‐evolutionary process.     

Genome-driven elucidation of phage-host interplay and impact of phage resistance evolution on bacterial fitness

When considering the interactions between bacteriophages and their host, the issue of phage-resistance emergence is a key element in understanding the ecological impact of phages on the bacterial population. It is also an essential parameter for the implementation of phage therapy to combat antibiotic-resistant pathogens. This study investigates the phenotypic and genetic responses of five Pseudomonas aeruginosa strains (PAO1, A5803, AA43, CHA, and PAK) to the infection by seven phages with distinct evolutionary backgrounds and recognised receptors (LPS/T4P). Emerging phage-insensitivity was generally accompanied by self and cross-resistance mechanisms. Significant differences were observed between the reference PAO1 responses compared to other clinical representatives. LPS-dependent phage infections in clinical strains selected for mutations in the “global regulatory” and “other” genes, rather than in the LPS-synthesis clusters detected in PAO1 clones. Reduced fitness, as proxied by the growth rate, was correlated with large deletion (20–500 kbp) and phage carrier state. Multi-phage resistance was significantly correlated with a reduced growth rate but only in the PAO1 population. In addition, we observed that the presence of prophages decreased the lytic phage maintenance seemingly protecting the host against carrier state and occasional lytic phage propagation, thus preventing a significant reduction in bacterial growth rate.Subject terms: Bacteriophages, Biodiversity     

Gut Microbiome Alterations in COVID-19

Since the outset of the coronavirus disease 2019 (COVID-19) pandemic, the gut microbiome in COVID-19 has garnered substantial interest, given its significant roles in human health and pathophysiology. Accumulating evidence is unveiling that the gut microbiome is broadly altered in COVID-19, including the bacterial microbiome, mycobiome, and virome. Overall, the gut microbial ecological network is significantly weakened and becomes sparse in patients with COVID-19, together with a decrease in gut microbiome diversity. Beyond the existence of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the gut microbiome of patients with COVID-19 is also characterized by enrichment of opportunistic bacteria, fungi, and eukaryotic viruses, which are also associated with disease severity and presentation. Meanwhile, a multitude of symbiotic bacteria and bacteriophages are decreased in abundance in patients with COVID-19. Such gut microbiome features persist in a significant subset of patients with COVID-19 even after disease resolution, coinciding with ‘long COVID’ (also known as post-acute sequelae of COVID-19). The broadly-altered gut microbiome is largely a consequence of SARS-CoV-2 infection and its downstream detrimental effects on the systemic host immunity and the gut milieu. The impaired host immunity and distorted gut microbial ecology, particularly loss of low-abundance beneficial bacteria and blooms of opportunistic fungi including Candida, may hinder the reassembly of the gut microbiome post COVID-19. Future investigation is necessary to fully understand the role of the gut microbiome in host immunity against SARS-CoV-2 infection, as well as the long-term effect of COVID-19 on the gut microbiome in relation to the host health after the pandemic.     

Atomic structure of bacteriophage Sf6 tail needle knob

Podoviridae are double-stranded DNA bacteriophages that use short, non-contractile tails to adsorb to the host cell surface. Within the tail apparatus of P22-like phages, a dedicated fiber known as the “tail needle” likely functions as a cell envelope-penetrating device to promote ejection of viral DNA inside the host. In Sf6, a P22-like phage that infects Shigella flexneri, the tail needle presents a C-terminal globular knob. This knob, absent in phage P22 but shared in other members of the P22-like genus, represents the outermost exposed tip of the virion that contacts the host cell surface. Here, we report a crystal structure of the Sf6 tail needle knob determined at 1.0 Å resolution. The structure reveals a trimeric globular domain of the TNF fold structurally superimposable with that of the tail-less phage PRD1 spike protein P5 and the adenovirus knob, domains that in both viruses function in receptor binding. However, P22-like phages are not known to utilize a protein receptor and are thought to directly penetrate the host surface. At 1.0 Å resolution, we identified three equivalents of l-glutamic acid (l-Glu) bound to each subunit interface. Although intimately bound to the protein, l-Glu does not increase the structural stability of the trimer nor it affects its ability to self-trimerize in vitro. In analogy to P22 gp26, we suggest the tail needle of phage Sf6 is ejected through the bacterial cell envelope during infection and its C-terminal knob is threaded through peptidoglycan pores formed by glycan strands.